About the Authors
- Clarisse Lorin
-
* E-mail: clarisse.m.lorin@gsk.com
Affiliation GSK Vaccines, Rixensart, Belgium
- Yannick Vanloubbeeck
-
Affiliation GSK Vaccines, Rixensart, Belgium
- Sébastien Baudart
-
Affiliation GSK Vaccines, Rixensart, Belgium
- Michaël Ska
-
Affiliation GSK Vaccines, Rixensart, Belgium
- Babak Bayat
-
Affiliation GSK Vaccines, Rixensart, Belgium
- Geoffroy Brauers
-
Affiliation GSK Vaccines, Rixensart, Belgium
- Géraldine Clarinval
-
Affiliation GSK Vaccines, Rixensart, Belgium
- Marie-Noëlle Donner
-
Affiliation GSK Vaccines, Rixensart, Belgium
- Martine Marchand
-
Affiliation GSK Vaccines, Rixensart, Belgium
- Marguerite Koutsoukos
-
Affiliation GSK Vaccines, Rixensart, Belgium
- Pascal Mettens
-
Affiliation GSK Vaccines, Rixensart, Belgium
- Joe Cohen
-
Affiliation GSK Vaccines, Rixensart, Belgium
- Gerald Voss
-
Affiliation GSK Vaccines, Rixensart, Belgium
Competing Interests
All authors declared that the following interests are relevant to the submitted work: All authors are, or were at the time of the study, employees of the GSK group of companies. JC now works as an independent consultant for GSK Vaccines. CL, YV, MK, GV, JC and PM report ownership of GSK shares. JC, CL, MK and GV are listed as inventors on patents owned by GSK. The F4 construct is disclosed in patent WO2006/013106: “Vaccine for prevention and treatment of HIV-infection”. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: CL YV MK GV JC BB PM. Performed the experiments: SB MS GB GC BB MND. Analyzed the data: CL YV BB. Wrote the paper: CL YV SB MS BB GB GC MND MM MK PM JC GV.